Barclays lowered the firm’s price target on TScan Therapeutics (TCRX) to $3 from $14 and keeps an Overweight rating on the shares post the Q4 report. The firm says that given the pullback in the stock, it “derisked the model” post the earnings print, focusing the model on transplant and head-neck with “conservative penetration.” The analyst still sees upside in the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- Positive Outlook for TScan Therapeutics: Buy Rating Affirmed Due to Promising TCR-T Cell Therapy Progress and Solid Financial Position
- Promising Clinical Differentiation and Strategic Advancements Drive Buy Rating for TScan Therapeutics
- Promising Progress and Strategic Expansion Position TScan Therapeutics for Success
- TScan Therapeutics Reports 2024 Financial Results and Progress
- TScan Therapeutics files $300M mixed securities shelf